Navigation Links
Medarex Announces 2007 Fourth Quarter and Year End Financial Results
Date:2/26/2008

ct development and business activities during the fourth quarter of 2007 include the following:

-- Announcing the receipt of a milestone payment from our licensing

partner, Centocor, Inc., in connection with Centocor's submission of

regulatory applications requesting approval of ustekinumab (CNTO 1275),

an anti-IL-12/IL-23 human antibody for the treatment of chronic

moderate to severe plaque psoriasis that was generated using Medarex's

UltiMAb(R) technology;

-- Announcing top-line data from the three registrational trials

evaluating ipilimumab as a monotherapy for the treatment of second-line

(previously treated) metastatic melanoma, with a goal to file a

Biologics License Application (BLA) in the first-half of 2008;

-- Filing an investigational new drug (IND) application with the U.S. Food

and Drug Administration (FDA) for MDX-1411, a fully human anti-CD70

antibody in development for the treatment of clear cell renal cancer;

-- Filing two separate INDs with the FDA for MDX-1342, a fully human anti-

CD19 antibody in development for the treatment of chronic lymphocytic

leukemia and for rheumatoid arthritis;

-- Filing an IND with the FDA for MDX-1106, a fully human anti-PD-1

antibody in development with Ono Pharmaceutical Co., Ltd, being

investigated for the treatment of chronic viral infections, with the

first trial to target hepatitis C; and

-- Receiving a milestone payment from Amgen, Inc., for the advancement of

Amgen's fifth UltiMAb(R)-derived antibody into clinical development.

In addition to fourth quarter events, other activities in 2007 include:

-- Presenting encouraging Phase 2 and Phase 1 clinical data from multiple

ipilimumab trials for the treatment of metastatic melanoma and prostate

cancer at the annual meeting of the American Society o
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Present at the JPMorgan Small/Mid Cap Conference
5. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
6. Grupo Casa Saba Announces Fourth Quarter 2007 Results
7. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
8. Reproductive Medicine Associates of Texas Announces Open House in San Antonio
9. WallSt.net (www.WallSt.net) Announces Upcoming Interview With Chairman and CEO of flexSCAN, Inc.
10. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
11. Thomson Healthcare Announces Enhancements to Order Sets Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... ... Throughout its 20 year history, Doctors on Liens has pioneered ... basis. As the personal injury and medical industries have changed, Doctors on Liens ... pain management physicians, to psychologists and more. And while many of these offices ...
(Date:7/27/2015)... ... July 27, 2015 , ... Recently, 10 Best Water ... respected water brands also made the organization’s list. As its name clearly indicates, 10 ... available. Here is a description of the top three brands, along with a listing ...
(Date:7/27/2015)... Dallas, Texas (PRWEB) , ... July 27, 2015 ... ... the use of fullerenes in medical and diagnostics applications is rapidly increasing and ... drug delivery and cancer treatment, they are increasingly being evaluated for use in ...
(Date:7/27/2015)... ... , ... Boston IVF, the first Massachusetts egg freezing center to assist in ... Nantucket Island for women who wish to learn more about their fertility and egg ... Chins Way, Nantucket Island 02554 from 4:30-6:30pm. , This casual and informative event will ...
(Date:7/27/2015)... ... 27, 2015 , ... Standifer Insurance Group, a locally owned insurance company with ... Conquest, a specialized camp for young people who have been hospitalized in the burn ... and four night curriculum designed to give burn survivors between the ages of 6-17 ...
Breaking Medicine News(10 mins):Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 2Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 3Health News:Standifer Insurance Group and Camp Conquest Plan Joint Charity Initiative to Assist Hospitalized Children Suffering from Burn Injuries 2Health News:Standifer Insurance Group and Camp Conquest Plan Joint Charity Initiative to Assist Hospitalized Children Suffering from Burn Injuries 3
... -- A common form of heart trouble called diastolic ... an increased risk of heart failure, new research shows. ... age, the heart,s left ventricle fills with blood in an ... The new study included more than 2,000 people aged ...
... HealthDay Reporter , TUESDAY, Aug. 23 (HealthDay News) -- ... regular medications for chronic conditions during their stay and ... say. Patients treated in the intensive care unit ... medication schedule after discharge, probably because there are so ...
... chemicals can be like putting together a puzzle. University ... the pieces together to more efficiently build complex molecules, ... by chemistry professor Martin Burke, the team published its ... Angewandte Chemie . Burke,s group is known for ...
... researchers have proposed in a new study a different ... using data from other similar chemicals. For ... have enough information to understand all of the effects ... this, the European Union enacted the REACH regulation, which ...
... patients treated at a U.S. military hospital in Afghanistan ... in the September issue of Infection Control and ... Healthcare Epidemiology of America. The findings underscore the need ... both soldiers and local patients are treated, the study,s ...
... -- The amount of fighting and arguing in your marriage ... study suggests. Ohio State University researchers looked at data ... 2000. Based on how often participants said they disagreed with ... high-conflict marriages. There was little change in any of ...
Cached Medicine News:Health News:Common Heart Dysfunction Can Help Bring on Heart Failure 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 3Health News:A new set of building blocks for simple synthesis of complex molecules 2Health News:Scientists develop new approaches to predict the environmental safety of chemicals 2Health News:Study: Afghan patients a common source of drug-resistant bacteria 2Health News:Couples Who Don't Fight Much Aren't Likely to Start 2
(Date:7/27/2015)... -- QT Vascular Ltd., together with its subsidiaries ("QT Vascular" ... design, assembly and distribution of advanced therapeutic solutions for ... into an agreement with a group of investors (the ... This funding will strengthen the Group,s working capital which ... Dr. Eitan Konstantino , Ph.D., ...
(Date:7/27/2015)... York , July 27, 2015 ... Research "Bionics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 7.96 billion in 2014, growing at a ... USD 20.49 billion in 2021. The global bionics ... number of accidents, which is leading to paralysis or amputation ...
(Date:7/27/2015)... , July 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ... Solaris therapeutic modality products. This approval allows the company to sell ... countries around the world. "Receiving the CE Mark represents ... stated Kelvyn H. Cullimore Jr. , president and CEO of ... network into China , Japan ...
Breaking Medicine Technology:QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Dynatronics Awarded CE Mark Approval for Its Solaris Products 2
... trauma or,noise-induced hearing loss. By any name, it,s the ... 28 million Americans,have impaired hearing; for as many as ... December 2007 issue of Harvard Men,s,Health Watch., Acoustic ... exposure,is the most common cause, but recreational noise -- ...
... Proven to Significantly Improve Overall Survival in ... Patients ... 19 ,Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX) today ... a supplemental New Drug Application for Nexavar(R) (sorafenib),tablets for the ...
Cached Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
... Richmond Products includes the four demonstration plates, the ... for a total of 24 plates. Each of ... and clean page selection. The test also includes ... laminated copy of the score sheet. The score ...
... charts are recognized internationally as a ... deficiency. With normal color perception, the ... visible. Each color test plate in ... printed to measure incrementally higher color ...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Medicine Products: